scholarly journals Urokinase Therapy in Neonates with Catheter Related Central Venous Thrombosis

1995 ◽  
Vol 73 (02) ◽  
pp. 180-185 ◽  
Author(s):  
M L G Wever ◽  
K D Liem ◽  
W B Geven ◽  
R B Tanke
Keyword(s):  
Venous Thrombosis ◽  
Oral Anticoagulants ◽  
Prophylactic Antibiotic ◽  
Fibrinolytic Therapy ◽  
Term Treatment ◽  
Central Venous ◽  
Long Term Treatment ◽  
Central Venous Thrombosis ◽  
Prophylactic Antibiotic Therapy ◽  
Therapy Success

SummaryThe results of fibrinolytic therapy with urokinase were evaluated in 26 neonates with catheter related central venous thrombosis. Complete thrombolysis could be achieved in 13 patients (50%), partial thrombolysis in 3 patients (12%). No effect was seen in 10 patients (38%). Therapy success was influenced by age, size and location of the thrombus. Coincidence of infection occurred in 16 patients (62%). Mild hemorrhagic complications were seen in 2 patients (8%), no other significant side effects were observed. Nine patients with residual thrombosis were treated with oral anticoagulants following urokinase resulting in resolution of the thrombus in 6 patients within 3 months (67%). The incidence of asymptomatic recurrent thrombosis was high (28%). Urokinase might be an effective and safe treatment for central venous thrombosis in neonates. Prophylactic antibiotic therapy during the infusion of urokinase and long-term treatment with oral anticoagulants after thrombosis are advisable. Early detection of thrombosis might enhance the success rate of fibrinolytic therapy. Therefore, we strongly recommend routine echocardiographic screening of central venous catheters.

scholarly journals Rivaroxaban for the treatment of cerebral venous thrombosis

BMC Neurology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Sara Esmaeili ◽  
Meysam Abolmaali ◽  
Sobhan Aarabi ◽  
Mohammad Reza Motamed ◽  
Samira Chaibakhsh ◽  
...  
Keyword(s):  
Venous Thrombosis ◽  
Cerebral Venous Thrombosis ◽  
Vitamin K Antagonists ◽  
Oral Anticoagulants ◽  
Bleeding Risk ◽  
Term Treatment ◽  
Background Information ◽  
Minor Bleeding ◽  
Long Term Treatment ◽  
Significant Difference

Abstract Background New Oral Anticoagulants (NOACs) such as Rivaroxaban are introduced as alternatives to conventional vitamin-K antagonists in the long-term treatment of thrombotic events due to their lower bleeding risk. There is a lack of evidence on the effectiveness and safety of Rivaroxaban in Cerebral venous thrombosis (CVT). This study aims to assess the effectiveness and bleeding risk of Rivaroxaban in comparison with Warfarin for the treatment of CVT. Materials and methods 36 patients with diagnosis of CVT were included. Clinical and background information was assessed on admission and patients were followed for at least 12 months. Measured outcomes were modified Rankin Scale (mRS), evidence of recanalization on contrast-enhanced Brain MR venography (MRV) and major or minor bleeding. Patients were divided into two groups according to the type of oral anticoagulant (Rivaroxaban vs Warfarin). Groups were compared in terms of final outcomes and side effects. Result Overall, 13 (36.11%) patients received Warfarin and 23 (63.89%) received Rivaroxaban. Optimal mRS score (0–1) was attained in 9 of 10 (90%) of patients treated with Rivaroxaban and 19 of 22 (86.36%) of patients received Warfarin. MRV showed complete or partial recanalization in 12 of 14 (85.71%) patients treated with Rivaroxaban and all patients in the Warfarin group. There was no significant difference between the two groups in terms of major and minor hemorrhage. Conclusion Rivaroxaban holds promise for the treatment of CVT.

scholarly journals Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis

2001 ◽  
Vol 33 (1) ◽  
pp. 77-90 ◽  
Author(s):  
Paloma López-Beret ◽  
Antonio Orgaz ◽  
Juan Fontcuberta ◽  
Manuel Doblas ◽  
Adela Martinez ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Venous Thrombosis ◽  
Deep Venous Thrombosis ◽  
Low Molecular Weight Heparin ◽  
Oral Anticoagulants ◽  
Term Treatment ◽  
Low Molecular Weight ◽  
Long Term Treatment

scholarly journals Report of a Young Female With Severe Abdominal Pain: Mesenteric Venous Thrombosis

2020 ◽  
Author(s):  
Ahmad Hormati ◽  
Faezeh Alemi ◽  
Rouhollah Taghavi ◽  
Mohammadreza Ghasemian ◽  
Mahsa Besharati
Keyword(s):  
Abdominal Pain ◽  
Venous Thrombosis ◽  
Young Female ◽  
Term Treatment ◽  
Severe Abdominal Pain ◽  
High Rate ◽  
Oral Contraceptive Pills ◽  
Delay In Diagnosis ◽  
Long Term Treatment ◽  
Drug History

Mesenteric ischemia is a rare disease with a high rate of mortality because of the non-specific symptoms which lead to delay in diagnosis and intervention. The main symptom is abdominal pain, which has a broad list of differential diagnoses. This study introduces a 17-year-old girl who presents to the emergency department with severe abdominal pain and hematemesis. Further evaluations revealed thrombosis in the mesenteric vein which leads to ischemia and gangrene of the small intestine. Her past medical history and drug history were negative, except she was taking levonorgestrel and cyproterone acetate for a 5 months period. Since long-term treatment with oral contraceptive pills, counts as a risk factor for venous thrombosis, this case seems to be uncommon. © 2019 Tehran University of Medical Sciences. All rights reserved. Acta Med Iran 2019;57(7):468-470.

Sign in / Sign up

Export Citation Format

Share Document